Pembrolizumab versus Methotrexate, Docetaxel, or Cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study
Checkpoint inhibitors in head and neck cancers
Chairpersons :
D. C. Doval, Ramesh Bilimagga
Reviewer :
Vanita Noronha